Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936310 | 0.86 | HSD11B1 (0.37) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL8309136 | 0.84 | HSD11B1 (0.36) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL14968800 | 0.83 | CHRNB2 (0.46) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL2719300 | 0.83 | GABRP (0.43) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL30484935 | 0.83 | CHRNB2 (0.44) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL13801425 | 0.81 | GNAI3 (0.53) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL4743326 | 0.81 | GNAI3 (0.49) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL17112610 | 0.80 | GABRP (0.44) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL16797329 | 0.80 | GABRP (0.44) | GNAI3GNAO1GNAI1L3MBTL3L3MBTL1 | |
| SCHEMBL23089850 | 0.79 | HSD11B1 (0.46) | L3MBTL3ITGB3ITGA2BTSHRMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880046-A1 | NOVEL CHARTREUSIN ANALOGUES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (DE) | 2015-06-10 | — | — | EP | claimed |
| WO-2014019685-A1 | NOVEL CHARTREUSIN ANALOGUES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2014-02-06 | — | — | WO | claimed |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4332100-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| EP-2035411-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | GPR119, HTR1D, TRPV1 | GNAI3 1210/4885GNAO1 945/4885GNAI1 892/4885 |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | GNAI3 1606/4885GNAO1 1547/4885GNAI1 1593/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | GNAI3 738/4885GNAO1 687/4885GNAI1 685/4885 |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAI3 439/4885GNAO1 222/4885GNAI1 405/4885 |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | AR, CYP19A1, ESRRA | GNAI3 1730/4885GNAO1 1299/4885GNAI1 1078/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | GNAI3 751/4885GNAO1 104/4885GNAI1 400/4885 |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | GNAI3 1871/4885GNAO1 2141/4885GNAI1 815/4885 |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, BCKDK, CYP11B2 | GNAI3 1138/4885GNAO1 854/4885GNAI1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.